Free Trial

Cormark Upgrades Curaleaf (OTCMKTS:CURLF) to "Moderate Buy"

Curaleaf logo with Medical background

Key Points

  • Curaleaf has been upgraded by Cormark from a "hold" rating to a "moderate buy" rating, signaling increased optimism from analysts.
  • Shares of Curaleaf saw a significant 14.0% increase on the day following the upgrade, opening at $2.04.
  • Despite a reported loss of ($0.06) EPS for the last quarter, Curaleaf exceeded analysts' expectations and is projected to post -0.25 EPS for the current year.
  • Need better tools to track Curaleaf? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Cormark upgraded shares of Curaleaf (OTCMKTS:CURLF - Free Report) from a hold rating to a moderate buy rating in a research report report published on Friday,Zacks.com reports.

Curaleaf Price Performance

CURLF stock traded down $0.04 during mid-day trading on Friday, hitting $2.72. The company had a trading volume of 3,230,749 shares, compared to its average volume of 738,370. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -8.50 and a beta of 0.69. Curaleaf has a 12-month low of $0.68 and a 12-month high of $3.58. The company has a quick ratio of 0.70, a current ratio of 1.41 and a debt-to-equity ratio of 1.08. The company has a 50-day moving average price of $1.11 and a 200 day moving average price of $1.06.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.41%. On average, research analysts anticipate that Curaleaf will post -0.25 earnings per share for the current year.

Curaleaf Company Profile

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Further Reading

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines